BP p.l.c. – Consensus Indicates Potential 20.0% Upside

DirectorsTalk Interviews

BP p.l.c. found using ticker (BP) now have 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 45 and 29 calculating the mean target price we have 36.85. Now with the previous closing price of 30.7 this indicates there is a potential upside of 20.0%. There is a 50 day moving average of 29.65 while the 200 day moving average is 29.83. The company has a market capitalisation of $95,377m. Company Website: https://www.bp.com

The potential market cap would be $114,484m based on the market concensus.

BP p.l.c. engages in the energy business worldwide. It operates through Gas & Low Carbon Energy, Oil Production & Operations, Customers & Products, and Rosneft segments. It produces and trades in natural gas; offers biofuels; operates onshore and offshore wind power, and solar power generating facilities; and provides de-carbonization solutions and services, such as hydrogen and carbon capture and storage. The company is also involved in the convenience and mobility business, which manages the sale of fuels to retail customers, convenience products, aviation fuels, and Castrol lubricants; and refining and trading of oil products, as well as operation of electric vehicle charging facilities. In addition, it produces and refines oil and gas; and invests in upstream, downstream, and alternative energy companies, as well as in advanced mobility, bio and low carbon products, carbon management, digital transformation, and power and storage areas. The company was founded in 1908 and is headquartered in London, the United Kingdom.

Share on:

Latest Company News

India’s smart meter rollout is building a broader digital grid opportunity

India’s smart-meter rollout is developing into a wider digital-grid ecosystem spanning connected hardware, communications, utility software, cybersecurity and energy analytics.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

    Search